上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2022 , Vol. 42 >Issue 6: 758 - 767

DOI: https://doi.org/10.3969/j.issn.1674-8115.2022.06.010

论著 · 基础研究

低剂量地西他滨对免疫性血小板减少症患者来源的骨髓间充质干细胞生物学行为的影响

  • 王昕芃 ,
  • 王君颖 ,
  • 蔡佳翌 ,
  • 付婉彬 ,
  • 钟华
展开
  • 1.上海交通大学医学院附属仁济医院血液科，上海 200127
    2.上海交通大学医学院附属仁济医院中心实验室，上海 200127
王昕芃（1996—），女，硕士生；电子信箱：wxpyoyo@126.com。
钟 华，电子信箱： zhh_lj@163.com。

收稿日期: 2022-02-11

  录用日期: 2022-05-11

  网络出版日期: 2022-08-19

基金资助

上海交通大学医学院附属仁济医院南院临床多学科合作共建项目(2014MDT01-07)

收起

Effect of low-dose decitabine on the biological behavior of bone marrow mesenchymal stem cells derived from patients with immune thrombocytopenia

  • Xinpeng WANG ,
  • Junying WANG ,
  • Jiayi CAI ,
  • Wanbing FU ,
  • Hua ZHONG
Expand
  • 1.Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
    2.Central Laboratory, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
ZHONG Hua，E-mail: zhh_lj@163.com.

Received date: 2022-02-11

  Accepted date: 2022-05-11

  Online published: 2022-08-19

Supported by

Program for Clinical Multi-Disciplinary Teamwork of Renji Hospital (South Campus), Shanghai Jiao Tong University School of Medicine(2014MDT01-07)

Fold

摘要

目的·研究低剂量地西他滨对原发免疫性血小板减少症（immune thrombocytopenia，ITP）患者来源的骨髓间充质干细胞（mesenchymal stem cell，MSC）增殖、凋亡等生物学行为的影响。方法·纳入2020年4月—2021年10月上海交通大学医学院附属仁济医院血液科门诊或住院的ITP发病期患者10例，以及10例无骨髓异常的非ITP患者作为对照（normal control，NC），收集骨髓穿刺标本，分离MSC，流式细胞术检测其表面抗原标志物。使用CCK-8试剂盒和EdU细胞增殖检测试剂盒检测及比较ITP患者来源（MSC-ITP）和对照组来源（MSC-NC）的MSC增殖水平差异，并使用微管荧光探针检测细胞形态的变化。使用Hoechst 33258染色观察细胞凋亡情况，采用Annexin V-FITC/PI细胞凋亡双染试剂盒检测细胞凋亡水平。通过不同浓度的地西他滨以不同的时长处理MSC-ITP，探索地西他滨促其增殖的最佳浓度及处理时间。以最佳浓度的地西他滨处理MSC-ITP，观察其对细胞凋亡水平的影响。Western blotting检测细胞凋亡相关通路蛋白的表达，以及地西他滨的影响。结果·与MSC-NC相比，MSC-ITP细胞形态异常，细胞核碎裂、皱缩较多，体外增殖水平减弱，基础凋亡率增加。地西他滨刺激MSC-ITP增殖的最佳工作浓度为2.5 μmol/L，最佳处理时间为24 h。2.5 μmol/L地西他滨处理MSC-ITP 24 h后细胞核形态得到改善，细胞核的碎裂和凝聚减少，凋亡率显著降低（P<0.05）。Western blotting结果表明，地西他滨处理后，MSC-ITP中线粒体凋亡通路相关蛋白BAX降低，胱天蛋白酶（caspase3）和cleaved-caspase3减少（均P<0.05）。结论·ITP患者骨髓来源的MSC形态异常，体外增殖水平减弱，基础凋亡率增加；低剂量地西他滨可以促进该细胞增殖，抑制其凋亡；该作用可能是通过线粒体凋亡途径介导的。

关键词： 免疫性血小板减少症; 骨髓间充质干细胞; 地西他滨; DNA甲基转移酶抑制剂; 细胞凋亡

本文引用格式

王昕芃 , 王君颖 , 蔡佳翌 , 付婉彬 , 钟华 . 低剂量地西他滨对免疫性血小板减少症患者来源的骨髓间充质干细胞生物学行为的影响[J]. 上海交通大学学报（医学版）, 2022 , 42(6) : 758 -767 . DOI: 10.3969/j.issn.1674-8115.2022.06.010

Abstract

Objective

·To investigate the effects of low-dose decitabine on the biological behaviors of proliferation and apoptosis of bone marrow mesenchymal stem cells (MSC) derived from the patients with primary immune thrombocytopenia (ITP).

Methods

·Ten patients with ITP onset who were outpatients or inpatients in the Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, from April 2020 to October 2021 were included, and 10 non-ITP patients without bone marrow abnormalities were included as controls (normal control, NC). The bone marrow aspiration specimens were collected, MSCs were isolated, and flow cytometry was used to detect their surface antigenic markers. Differences in MSC proliferation levels between the ITP patients (MSC-ITP) and the controls (MSC-NC) were detected by using the CCK-8 kit and the EdU cell proliferation assay kit, and the changes in cell morphology were detected by using microtubule fluorescent probes. Apoptosis was observed by using Hoechst 33258 staining, and the level of apoptosis was detected by using Annexin V-FITC/PI apoptosis double-staining kit. The optimal concentration and treatment time of decitabine to promote the proliferation of MSC-ITP were explored by treatment with different concentrations and different durations. Western blotting was performed to detect the expression of apoptosis-related proteins and the effect of decitabine.

Results

·Compared with MSC-NC, MSC-ITP showed abnormal morphology, more nuclear fragmentation and crinkling, reduced proliferation level in vitro, and increased basal apoptosis rate. The optimal working concentration of decitabine to stimulate MSC-ITP proliferation was 2.5 μmol/L, and the optimal treatment time was 24 h. After 2.5 μmol/L decitabine treating MSC-ITP for 24 h, cell nuclear morphology was improved, nuclei fragmentation and coalescence were reduced, and apoptosis rate was significantly decreased (P<0.05). Western blotting results showed that BAX, a mitochondrial apoptosis pathway-related protein, cystatin protease 3 (caspase3) and cleaved-caspase3 were reduced in MSC-ITP after treatment with decitabine (P<0.05).

Conclusion

·The MSCs originating from ITP patients' bone marrow have abnormal morphology, reduced proliferation level and increased basal apoptosis rate in vitro; low-dose decitabine can promote the proliferation and inhibit the apoptosis of the cells, which may be mediated through the mitochondrial apoptosis pathway.

Key words： immune thrombocytopenia (ITP); bone marrow mesenchymal stem cell; decitabine; DNA methyltransferase inhibitor; apoptosis

参考文献

1 SEMPLE J W, PROVAN D, GARVEY M B, et al. Recent progress in understanding the pathogenesis of immune thrombocytopenia[J]. Curr Opin Hematol, 2010, 17(6): 590-595.
2 REEMS J A, PINEAULT N, SUN S J. In vitro megakaryocyte production and platelet biogenesis: state of the art[J]. Transfus Med Rev, 2010, 24(1): 33-43.
3 GLENNIE S, SOEIRO I, DYSON P J, et al. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells[J]. Blood, 2005, 105(7): 2821-2827.
4 TABERA S, PéREZ-SIMóN J A, DíEZ-CAMPELO M, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes[J]. Haematologica, 2008, 93(9): 1301-1309.
5 TASSO R, ILENGO C, QUARTO R, et al. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis[J]. Invest Ophthalmol Vis Sci, 2012, 53(2): 786-793.
6 MA J, NING Y N, XU M, et al. Thalidomide corrects impaired mesenchymal stem cell function in inducing tolerogenic DCs in patients with immune thrombocytopenia[J]. Blood, 2013, 122(12): 2074-2082.
7 PéREZ-SIMóN J A, TABERA S, SARASQUETE M E, et al. Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura[J]. Cytotherapy, 2009, 11(6): 698-705.
8 ZHANG D L, LI H Y, MA L, et al. The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia[J]. Autoimmunity, 2014, 47(8): 519-529.
9 王君颖, 李昕, 殷婷玉, 等. 免疫性血小板减少症患者来源的骨髓间充质细胞对巨核细胞生物学行为的影响[J]. 上海交通大学学报(医学版), 2018, 38(6): 616-623.
9 WANG J Y, LI X, YIN T Y, et al. Effects of bone marrow mesenchymal cells from immune thrombocytopenia patients on the biological behaviors of megakaryocytes[J]. J Shanghai Jiao Tong Univ (Med Sci), 2018, 38(6): 616–625.
10 XIAO J H, ZHANG C R, ZHANG Y C, et al. Transplantation of adipose-derived mesenchymal stem cells into a murine model of passive chronic immune thrombocytopenia[J]. Transfusion, 2012, 52(12): 2551-2558.
11 ZHANG P, ZHANG G, LIU X, et al. Mesenchymal stem cells improve platelet counts in mice with immune thrombocytopenia[J]. J Cell Biochem, 2019. DOI: 10.1002/jcb.28405.
12 WANG X H, YIN X G, SUN W, et al. Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: a two-year follow-up[J]. Exp Ther Med, 2017, 13(5): 2255-2258.
13 LEE S, KIM H S, ROH K H, et al. DNA methyltransferase inhibition accelerates the immunomodulation and migration of human mesenchymal stem cells[J]. Sci Rep, 2015, 5: 8020.
14 LIU S Y, SHAN N N. DNA methylation plays an important role in immune thrombocytopenia[J]. Int Immunopharmacol, 2020, 83: 106390.
15 ASSIS R I F, WIENCH M, SILVéRIO K G, et al. RG108 increases NANOG and OCT4 in bone marrow-derived mesenchymal cells through global changes in DNA modifications and epigenetic activation[J]. PLoS One, 2018, 13(12): e0207873.
16 OH Y S, JEONG S G, CHO G W. Anti-senescence effects of DNA methyltransferase inhibitor RG108 in human bone marrow mesenchymal stromal cells[J]. Biotechnol Appl Biochem, 2015, 62(5): 583-590.
17 OH Y S, KIM S H, CHO G W. Functional restoration of amyotrophic lateral sclerosis patient-derived mesenchymal stromal cells through inhibition of DNA methyltransferase[J]. Cell Mol Neurobiol, 2016, 36(4): 613-620.
18 ZHOU H, HOU Y, LIU X N, et al. Low-dose decitabine promotes megakaryocyte maturation and platelet production in healthy controls and immune thrombocytopenia[J]. Thromb Haemost, 2015, 113(5): 1021-1034.
19 RODEGHIERO F, STASI R, GERNSHEIMER T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group[J]. Blood, 2009, 113(11): 2386-2393.
20 LAMBERT M P, GERNSHEIMER T B. Clinical updates in adult immune thrombocytopenia[J]. Blood, 2017, 129(21): 2829-2835.
21 SHEN Y, NILSSON S K. Bone, microenvironment and hematopoiesis[J]. Curr Opin Hematol, 2012, 19(4): 250-255.
22 SONG Y, WANG Y T, HUANG X J, et al. Abnormalities of the bone marrow immune microenvironment in patients with immune thrombocytopenia[J]. Ann Hematol, 2016, 95(6): 959-965.
23 TAO Y L, SONG D X, ZHANG F Y, et al. Transplantation of bone-marrow-derived mesenchymal stem cells into a murine model of immune thrombocytopenia[J]. Blood Coagul Fibrinolysis, 2017, 28(8): 596-601.
24 LI H Y, XUAN M, YANG R C. DNA methylation and primary immune thrombocytopenia[J]. Semin Hematol, 2013, 50(Suppl 1): S116-S126.
25 WANG J H, YI Z H, WANG S Y, et al. The effect of decitabine on megakaryocyte maturation and platelet release[J]. Thromb Haemost, 2011, 106(2): 337-343.
26 HAN P P, HOU Y, ZHAO Y J, et al. Low-dose decitabine modulates T cell homeostasis and restores immune tolerance in immune thrombocytopenia[J]. Blood, 2021, 138(8): 674-688.
27 WANG Y, WANG F X, WEN S P, et al. Artesunate-enhanced apoptosis of human high-risk myelodysplastic cells induced by the DNA methyltransferase inhibitor decitabine[J]. Oncol Lett, 2015, 9(6): 2449-2454.
28 ZHANG G, GAO X H, ZHAO X Y, et al. Decitabine inhibits the proliferation of human T-cell acute lymphoblastic leukemia molt4 cells and promotes apoptosis partly by regulating the PI3K/AKT/mTOR pathway[J]. Oncol Lett, 2021, 21(5): 340.
29 WANG L, AMOOZGAR Z, HUANG J, et al. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model[J]. Cancer Immunol Res, 2015, 3(9): 1030-1041.
30 RüGER B M, BUCHACHER T, GIUREA A, et al. Vascular morphogenesis in the context of inflammation: self-organization in a fibrin-based 3D culture system[J]. Front Physiol, 2018, 9: 679.
31 ELMORE S. Apoptosis: a review of programmed cell death[J]. Toxicol Pathol, 2007, 35(4): 495-516.
32 FERRI K F, KROEMER G. Mitochondria: the suicide organelles[J]. BioEssays, 2001, 23(2): 111-115.
Options
文章导航

/

〈 〉